Inhibitors Of PAI-1 For Treatment Of Muscular Conditions
申请人:Crandall LeRoy David
公开号:US20070203220A1
公开(公告)日:2007-08-30
This invention describes novel methods of treating muscle damage, muscle wasting, muscle degeneration, muscle atrophy or reduced rates of muscle repair associated with various conditions such as muscular dystrophy, through the use of small-molecule PAI-1 inhibitors.
Substituted dihydropyrano indole-3,4-dione derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
申请人:Elokdah M. Hassan
公开号:US20050113436A1
公开(公告)日:2005-05-26
Compounds of formula (I) and II) are provided
wherein: X is an alkali metal or a basic amine moiety; R
1
is alkyl, cycloalkyl, —CH
2
-cycloalkyl, pyridinyl, —CH
2
-pyridinyl, phenyl or benzyl, the rings of these groups being optionally substituted; R
2
is H, halogen, alkyl, perfluoroalkyl, alkoxy, cycloalkyl, —CH
2
-cycloalkyl, —NH
2
, or —NO
2
; R
3
is phenyl, benzyl, benzyloxy, pyridinyl, or —CH
2
-pyridinyl, with the rings of these groups being optionally substituted; or a pharmaceutically acceptable salt or ester form thereof, as well as pharmaceutical compositions and methods using these compounds as inhibitors of plasminogen activator inhibitor-1 (PAI-1) and as therapeutic compositions for treating conditions resulting from fibrinolytic disorders such as deep vein thrombosis and coronary heart disease, and pulmonary fibrosis.